TABLE 3.
Peptidic GLP-1R agonists that have been launched or are in late-stage clinical trials
| Analog | Description | Company | Dosing Regimen | Status |
|---|---|---|---|---|
| Exenatide | Exendin-4 | Amylin/Eli Lilly; AstraZeneca | Twice daily | Launched |
| Exenatide once weekly | Exendin-4 | Amylin/Alkermes/Eli Lilly; AstraZeneca | Once weekly | Launched |
| Lixisenatide | Exendin-4 analog | Sanofi-Aventis | Once daily | Launched |
| Liraglutide | GLP-1 analog linked with a fatty acid | Novo Nordisk | Once daily | Launched |
| Albiglutide | GLP-1 analog fused to albumin | GlaxoSmithKline | Once weekly | Launched |
| Dulaglutide | GLP-1 analog fused to Fc | Eli Lilly | Once weekly | Launched |
| Semaglutide | GLP-1 analog linked with a fatty acid | Novo Nordisk | Once weekly | Phase 3 |
| Semaglutide (NN9924) | GLP-1 analog linked with a fatty di-acid | Novo Nordisk | Oral | Phase 2 |
| Taspoglutide | GLP-1 analog formulated for sustained release | Roche | Once weekly | Suspended |